The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02858557 |
Recruitment Status : Unknown
Verified August 2016 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Not yet recruiting
First Posted : August 8, 2016
Last Update Posted : August 8, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Inflammatory Bowel Diseases Crohn's Disease Dietary Modification | Behavioral: Mediterranean diet Behavioral: Specific Carbohydrate Diet | Not Applicable |
Increasing evidence exist regarding the role of diet in the pathogenesis of inflammatory bowel diseases. One possible mechanism for the effect of diet on intestinal inflammation is modification of the gut microbial composition. However, the relationship between diet, the microbiome and intestinal inflammation is still vague.
The investigators plan to perform a crossover clinical trial. Seventy ulcerative colitis patients post restorative proctocolectomy (pouch) will be randomly allocated into two short-term (one week) dietary interventions, the Mediterranean diet and the specific carbohydrate diet, to assess which diet has the required influence (i.e. increased diversity, decrease in specific pathobionts and increase in "anti-inflammatory" taxa) on the gut microbiome of each participant. Based on this assessment, each participant will be treated by a personally-tailored diet for up to one year, during which microbial composition, clinical parameters, and quality of life will be assessed.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 70 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Double (Participant, Care Provider) |
Primary Purpose: | Treatment |
Official Title: | The Effect of the Mediterranean Diet and the Specific Carbohydrate Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases |
Study Start Date : | September 2016 |
Estimated Primary Completion Date : | September 2018 |
Estimated Study Completion Date : | September 2018 |

Arm | Intervention/treatment |
---|---|
Experimental: Group A
Patients will be allocated to 7 days of Mediterranean diet and then will cross over to 7 days of specific carbohydrate diet
|
Behavioral: Mediterranean diet
The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats. Behavioral: Specific Carbohydrate Diet The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides. |
Experimental: Group B
Patients will be allocated to 7 days of specific carbohydrate diet and then will cross over to 7 days of Mediterranean diet
|
Behavioral: Mediterranean diet
The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats. Behavioral: Specific Carbohydrate Diet The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides. |
- Microbial diversity [ Time Frame: 7 days ]Shannon α-diversity index
- Clinical score [ Time Frame: 7 days ]Pouchitis Disease Activity Index (PDAI)
- C-reactive protein (CRP) [ Time Frame: 7 days ]Inflammatory marker
- fecal calprotectin [ Time Frame: 7 days ]Inflammatory marker
- Quality of life [ Time Frame: 7 days ]Inflammatory bowel diseases questionnaire (IBDQ)
- Microbial composition [ Time Frame: 7 days ]Change in the abundance of microbial taxa

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients aged 18-75;
- Able and willing to sign an informed consent;
- Underwent pouch surgery because of refractory UC or Familial Adenomatous Polyposis (FAP) and have a functioning pouch.
Exclusion Criteria:
- Patients with ileostomy, stricturing disease, use of antibiotics in the month prior to inclusion, significant comorbidity that precludes the patient from participating according to the physicians' judgment, non-Hebrew readers, pregnant and lactating women.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02858557
Contact: Lihi Godny, B.Sc | +9723947305 | lihig@tlvmc.gov.il |
Israel | |
Dep. of Gastroenterology, Tel Aviv Sourasky Medical Center | |
Tel Aviv, Israel |
Principal Investigator: | Iris Dotan, MD | Head, IBD center, Department of gastroenterology and liver diseases, Tel Aviv Sourasky Medical Center |
Responsible Party: | Tel-Aviv Sourasky Medical Center |
ClinicalTrials.gov Identifier: | NCT02858557 |
Other Study ID Numbers: |
0240-16-TLV |
First Posted: | August 8, 2016 Key Record Dates |
Last Update Posted: | August 8, 2016 |
Last Verified: | August 2016 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Crohn Disease Intestinal Diseases Inflammatory Bowel Diseases |
Gastroenteritis Gastrointestinal Diseases Digestive System Diseases |